Prostate Cancer

A recent study reveals that medication burden significantly increases acute care use in older metastatic prostate cancer patients on androgen receptor inhibitors.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

New research reveals enzalutamide combined with leuprolide significantly enhances survival rates in high-risk prostate cancer patients, setting a new standard of care.

New research shows that adding apalutamide to androgen deprivation therapy significantly improves outcomes for patients with recurrent prostate cancer.

New trial results reveal capivasertib enhances survival in advanced prostate cancer, offering hope for patients with PTEN deficiency.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

A new treatment regimen for metastatic prostate cancer shows significant reductions in severe adverse events, offering a promising alternative for patients.

New findings reveal that combining niraparib with abiraterone significantly extends progression-free survival in patients with HRR-altered metastatic prostate cancer.

Recent analysis reveals that rectal spacers significantly lower recurrence rates in prostate cancer patients undergoing radiation therapy, enhancing treatment outcomes.

A phase 2 trial reveals PSMA-PET–guided salvage radiotherapy significantly enhances cancer control in patients with prostate cancer post surgery.

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP inhibitors, and innovative PROTAC therapies.

A new treatment combination shows promise in extending progression-free survival for advanced prostate cancer patients, highlighting innovative cancer therapies.

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.

During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive prostate cancer.

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic prostate cancer patients, regardless of genetic factors.

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE trial.

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate cancer.

Alicia Morgans, MD, MPH, covers what sets darolutamide apart from other androgen receptor inhibitors.

Alicia Morgans, MD, MPH, discusses how the ARANOTE trial not only demonstrated clinical efficacy for the combination of ADT and darolutamide, but also highlighted key quality-of-life benefits that could help inform patient and physician conversations.

Alicia Morgans, MD, MPH, discusses the ARANOTE trial.

An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety monitoring including complete blood count (CBC) tracking, and practical management of adverse effects such as fatigue and nausea while following radiation safety protocols.